Drug Combo Radically Reduces Recurrent Colorectal Adenomas
ISSUE: MAY, 2008
A combination of the targeted agent difluoromethylornithine (DFMO) at a low dose and sulindac, a nonsteroidal anti-inflammatory drug, appears to reduce the risk for recurrent colorectal adenomas by up to 95% with less toxicity than chemotherapy, according to a Phase III trial.
read more |
In HER2-Positive Patients…Breast Cancer Vaccine May Reduce Mortality by 50%
ISSUE: MAY, 2008
Women with breast cancer that over-expresses HER2/neu appear to respond well to a new HER2 E75 peptide vaccine and have a 50% absolute reduction in mortality compared with controls, according to results from a Phase II trial by Texas researchers. Rather unexpectedly, the researchers also found that women with tumors that are low expressers of HER2 exhibited a better response to treatment, not only immunologically but also clinically, with a decreased recurrence of breast cancer and no mortality following vaccination.
read more |
The Cost of Extending Life
ISSUE: MAY, 2008
At the New Mexico Cancer Center in Albuquerque, a breast cancer patient recently approached Barbara L. McAneny, MD, wanting to switch from oral chemotherapy to intravenous chemotherapy. The issue wasn’t the effectiveness of capecitabine (Xeloda, Roche Laboratories)—it was the cost.
read more |
The Right Stuff
Evaluating Business Opportunities and Investments
ISSUE: MAY, 2008
Physicians today are increasingly involved in business and financial opportunities that include limited liability companies, partnerships, joint ventures, capital purchases, real estate and other investments. The two biggest mistakes people can make are to invest for the wrong reason and not do homework before taking the plunge. This article provides basic insight into some of the business and legal issues that a physician should keep in mind when evaluating an opportunity.
read more |